Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches

Executive Summary

Amgen and Allergan launched the first US biosimilar for Roche's Herceptinand the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Scrip's infographic reviews Herceptin's past and its future competitors.

You may also be interested in...



Bucking Biosimilar Threat, Roche Sees Further Growth

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches

Amgen and Allergan’s launch of the first biosimilars to Roche/Genentech’s Avastin and Herceptin may not face the same commercial dynamics that have stymied biosimilars in other therapeutic areas, but uptake could depend upon oncologists’ comfort level in prescribing the follow-on agents.

Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product

Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel